Abstract
Drug interactions with HIV medications are complex. When managing concurrent cardiovascular disease, statins, antiplatelets, anticoagulants, and antihypertensives are among select classes that are likely to lead to significant interactions. The greatest risk of drug interactions is associated with the use of cobicistat- or ritonavir-boosted HIV regimens. The lowest risk of drug interactions is associated with the use of raltegravir, dolutegravir, bictegravir, or rilpivirine-containing regimens. Providers are encouraged to use online databases for drug interaction screening when changing a medication used in managing cardiovascular disease or when altering any HIV regimen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 25, 2018. Available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/. Accessed 10 Jan 2019.
Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320(4):379–96
Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med. 2001;34(13):984–96.
Hansten PD. Drug interactions. In: Koda-Kimble MA, editor. Applied therapeutics: the clinical use of drugs. Vancouver: Applied Therapeutics, Inc.; 1995. p. 1–3.
ILO B. Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action, and elimination. In: Brunton LL, editor. Goodman and Gilman’s the pharmacologic basis of therapeutics. 11th ed. New York: McGraw Hill; 2005. p. 1–40.
Tivicay [package insert]. Research Triangle Park: ViiV Healthcare; 2016.
Isentress [package insert]. Whitehouse Station: Merck; 2016.
Norvir [package insert]. North Chicago: AbbVie; 2016.
Genvoya [package insert]. Foster City: Gilead; 2017.
Sustiva [package insert]. Princeton: Bristol-Myers Squib; 2017.
Viramune XR [package insert]. Ridgefield: Boehringer Ingelheim; 2017.
Edurant [package insert]. Titusville: Janssen; 2015.
Intellence [package insert]. Titusville: Janssen; 2014.
Pradaxa [package insert]. Ridgefield: Boehringer Ingelheim; 2015.
Apixiban [package insert]. Princeton: Bristol-Myers Squib; 2016.
Xarelto [package insert]. Titusville: Janssen; 2016.
Savaysa [package insert]. Parsippany: Daiichi Sankyo; 2015.
Kwong LM, Tong LM. Drug interactions with rivaroxaban following total joint replacement surgery. Ann Pharmacother. 2012;46:1232–8.
Bates D, Dalton B, Gilmour J. Venous thromboembolism due to suspected interaction between rivaroxaban and nevirapine. Can J Hosp Pharm. 2013;66:125–9.
Perram J, Joseph J, Holloway C. Novel oral anticoagulants and HIV: dabigatran use with Antiretrovirals. BMJ Case Rep. 2015;20. PUBMED ID 26590187. https://doi.org/10.1136/bcr-2015-211651.
Egan G, Hughes CA, Ackman ML. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother. 2014;48(6):734–40.
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.
O’Gara PT, Kushner FG, Ascheim DD. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:e78–e140.
Brillinta [package insert]. Wilmington: AstraZeneca; 2016.
Plavix [package insert]. Princeton: Bristol-Myers Squib; 2016.
Effient [package insert]. Indianapolis: Eli Lill; 2015.
Farid NA, Jakubowski JA, Payne CD. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Curr Med Res Opin. 2009;25:1821–9.
Ancrenaz V, Déglon J, Samer C, Staub C, Dayer P, Daali Y, et al. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin Pharmacol Toxicol. 2013;112(2):132–7.
Sharma GK, Megaly M. Etravirine as a culprit in recurrent drug-eluting in-stent restenosis in an HIV patient. Int J Cardiol. 2016;219:117–8.
Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011;50(1):25–39.
Marsousi N, Samer CF, Fontana P, Reny JL, Rudaz S, Desmeules JA, et al. Coadministration of ticagrelor and ritonavir: toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clin Pharmacol Ther. 2016;100(3):295–304.
Stone NJ, Robinson J, Lichtenstein AH, Bairey MCN, Blum CB, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;129:S1–S45.
Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV medical association of the infectious diseases society of America and the adult AIDS clinical trials group. Clin Infect Dis. 2003;37:613–27.
Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med. 2007;20(4):411–6.
Cheng CH, Miller C, Lowe C, Pearson VE. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm. 2002;59(8):728–30.
Aboulafia DM, Johnston R. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Patient Care STDs. 2000;14(1):13–8.
Hare CB, Vu MP, Grunfeld C, Lampiris HW. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis. 2002;35(10):e111–2.
Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: AIDS clinical trials group (ACTG) study A5047. AIDS. 2002;16:569–77.
Hulgan T, Sterling TR, Daugherty J, Arbogast PG, Raffanti S, Ray W. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. JAIDS. 2005;38(3):277–82.
Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS clinical trials group 5108 study. JAIDS. 2005;39:307–12.
Mikhail N, Iskander E, Cope D. Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin. Curr Drug Saf. 2009;4(2):121–2.
Aberg JA, Zackin RA, Brobst SW, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS clinical trials group study 5087. AIDS Res Hum Retrovir. 2005;21:757–67.
Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother. 2001;45(12):3445–50.
Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDs. 2003;17(5):207–10.
Castro JG, Gutierrez L. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am J Med. 2002;112(6):505.
Van der Lee M, Sankatsing R, Schippers E, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther. 2007;12:1127–32.
Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. JAIDS. 2008;47(5):570–8.
Busti AJ, Bain AM, Hall RG, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol. 2008;51(6):605–10.
Yu CY, Campbell SE, Sponseller CA, et al. Steady-state pharmacokinetic interactions of darunavir/ritonavir with pitavastatin in healthy adult volunteers. In: Program and abstracts of the XIX International AIDS Conference, July 22–27, 2012; Washington, DC. Abstract TUPE053.
Sponseller C, et al. Pitavastatin 4 mg provides greater low-density lipoprotein cholesterol reduction compared to pravastatin 40 mg over 12 weeks of treatment in HIV+ adults with dyslipidemia 20th conference on retroviruses and opportunistic infections. Atlanta Georgia, March 3–6. Abstract 187LB.
Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidemia (INTREPID): 12 week and 52 week results of a phase 4, multicenter, randomized, double blind, superiority trial. Lancet HIV. 2017;4(4) https://doi.org/10.1016/S2352-3018(17)30075-9.
Evaluating the use of pitavastatin to reduce the risk of cardiovascular disease in HIV-infected adults (REPRIEVE). Located at https://clinicaltrials.gov/ct2/show/NCT02344290
Busse KH, Hadigan C, Chairez C, et al. Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. JAIDS. 2009;52:235–9.
Reyataz [package insert]. Princeton: Bristol-Myers Squib; 2016.
Baeza MT, Merino E, Boix V, Vliment E. Nifedipine-lopinavir/ritonavir severe interaction: a case report. AIDS. 2007;21(1):119–20.
Rossi DR, Rathburn RC, Slater LN. Symptomatic orthostasis with extended-release nifedipine and protease inhibitors. Pharmacotherapy. 2002;22(10):1312–6.
Naccarato M, Yoong D, la Porte C, Fong I. Amiodarone and concurrent antiretroviral therapy: a case report and review of the literature. Antivir Ther. 2014;19(4):329–39.
Invirase [package insert]. South San Francisco: Genentech; 2015.
Aptivus [package insert]. Ridgefield: Boehringer Ingelheim; 2016.
Tikosyn [package insert]. New York: Pfizer; 2016.
Biktarvy [package insert]. Foster City:Gilead; 2018.
Schmitt C, Kaeser B, Riek M, Bech N, Kreuzer C. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. Int J Clin Pharmacol Ther. 2010;48(3):192–9.
Hunt K, Hughes CA, Hills-Nieminen C. Protease inhibitor-associated QT interval prolongation. Ann Pharmacother. 2011;45(12):1544–50.
Drew BJ, et al. Prevention of torsades de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55(9):934–47.
QTDrugs Lists. Located at https://crediblemeds.org/. Accessed 5 May 2017.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Faragon, J.J., Patel, N. (2019). Cardiovascular and HIV Drug Interactions. In: Myerson, M., Glesby, M. (eds) Cardiovascular Care in Patients With HIV. Springer, Cham. https://doi.org/10.1007/978-3-030-10451-1_15
Download citation
DOI: https://doi.org/10.1007/978-3-030-10451-1_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-10450-4
Online ISBN: 978-3-030-10451-1
eBook Packages: MedicineMedicine (R0)